Ojo-Publico.com identificó a empresas que monopolizan medicamentos contra el cáncer.
An investigation by Ojo-Publico.com reveals the economic impact of tax privileges that for 17 years have favored laboratories selling drugs for the treatment of cancer, HIV and diabetes. These benefits, which have not been passed on in the form of a lower medicine prices, have been audited by an executive commission. However, after seven years this group is yet to make its reports public.
Johnson & Johnson y Pzifer se ahorraron cuatro millones de dólares en pago de impuestos a la Sunat.